ProCE Banner Activity

Daratumumab + Rd vs Rd Alone in Relapsed/Refractory Myeloma: Extended Follow-up From POLLUX

Slideset Download
Conference Coverage
Extended follow-up continues to demonstrate significant increase in PFS with addition of daratumumab to lenalidomide/dexamethasone for patients with relapsed/refractory myeloma.

Released: December 19, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology